Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Double-target chimeric antigen receptor targeting CLL1 and NKG2D ligands and application thereof

A chimeric antigen receptor and dual-target technology, applied in the field of biomedicine, can solve problems such as reducing the recurrence rate of the disease, and achieve the effects of reducing the probability of disease recurrence, solving the problem of tumor antigen heterogeneity, and achieving a significant killing effect.

Active Publication Date: 2021-08-13
GUANGZHOU BIO GENE TECH CO LTD
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] However, there are currently few CAR-T technologies that co-target NKG2D ligands and AML antigens to reduce disease recurrence rates

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Double-target chimeric antigen receptor targeting CLL1 and NKG2D ligands and application thereof
  • Double-target chimeric antigen receptor targeting CLL1 and NKG2D ligands and application thereof
  • Double-target chimeric antigen receptor targeting CLL1 and NKG2D ligands and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0096] Example 1 Design of Chimeric Antigen Receptor

[0097] This example uses anti-CLL1 antibody H27H4 (SEQ ID NO: 1 ~ 2), 1075.7 (SEQ ID NO: 3 ~ 4) or 27H4 (SEQ ID NO: 5 ~ 6) and NKG2D extracellular segment (NKG2D-ECD, SEQ ID NO:7) as the antigen-binding domain, combined with CD8α signal peptide (SEQ ID NO:16~17) or IgGκ light chain signal peptide (SEQ ID NO:34~35), CD8α hinge region (SEQ ID NO:18~ 19) and transmembrane region (SEQ ID NO:20~21), 4-1BB co-stimulatory domain (SEQ ID NO:22~23) and CD3ζ signaling domain (SEQ ID NO:24~25), construct target The dual-target CAR (SEQ ID NO: 8-13) to CLL1 and NKG2D ligand (NKG2DL), the structural diagram is as follows Figure 1A shown;

[0098] This example also constructed an anti-CLL1 single-target CAR (SEQ ID NO: 26-27, SEQ ID NO: 28-29, SEQ ID NO: 30-31) and an anti-NKG2DL single-target CAR (SEQ ID NO: 32- 33), the structural diagram is as follows Figure 1B shown.

[0099] The relevant information of CAR molecules is shown ...

Embodiment 2

[0102] Example 2 Construction of Chimeric Antigen Receptor Expression Vector

[0103] (1) According to the CAR molecule designed in Example 1, the codon of the CAR coding gene was optimized to promote its high expression in human cells, and the CAR coding gene was synthesized from the whole gene (Guangzhou Aiji Biotechnology Co., Ltd.);

[0104] (2) The full-length CAR gene and the empty vector pCDH-EF1-MCS were digested with EcoRI and BamHI, digested in a water bath at 37°C for 30 min, and then subjected to DNA electrophoresis using 1.5% agarose gel, and purified using agarose gel The recovery kit (Tiangen) purifies and recovers the digested product;

[0105] (3) Prepare the ligation system shown in Table 2, ligate the CAR gene fragment and linearized pCDH-EF1-MCS at 22°C for 1 h, transform the ligated product directly into Stbl3 E. coli competent cells, take 200 μL of the transformed product and coat it with ampicillin LB plates were cultured upside down in a 37°C incubator...

Embodiment 3

[0109] Example 3 lentiviral packaging

[0110] In this example, the four-plasmid system is used to package the lentiviral expression vector with lentivirus, and the specific steps are as follows:

[0111] (1) After mixing the four-plasmid system composed of lentiviral expression vector, helper plasmid gag / pol, Rev, and VSV-G with PEI transfection reagent, add it to a certain volume of serum-free DMEM, mix it and place it for 15 minutes;

[0112] (2) Add the above mixture to the T75 cell culture flask covered with 293T cells, mix gently, and store at 37°C, 5% CO 2 Cultivate for 6 hours in a cell culture incubator;

[0113] (3) After 6 hours, replace the fresh medium, continue the culture, and add 10 mM sodium butyrate solution; after 72 hours, collect the lentivirus culture supernatant for purification and detection.

[0114] The titers of the packaged lentivirus are shown in Table 3.

[0115] table 3

[0116] CAR lentivirus Titer (TU / mL) NKG2D-CAR 8.35E7 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a double-target chimeric antigen receptor targeting CLL1 and a NKG2D ligand and application thereof. The double-target chimeric antigen receptor comprises a signal peptide, an antigen binding structural domain, a hinge region, a transmembrane structural domain and a signal transduction structural domain, and the antigen binding domain comprises an anti-CLL1 antibody and NKG2D. The CAR molecule simultaneously targeting CLL1 and the NKG2D ligand is constructed, the effect of comprehensively targeting acute myelogenous leukemia cells is achieved, the CAR-T cells for expressing the double-target CAR targeting CLL1 and the NKG2D ligand are remarkable in tumor removal effect, the antigen escape phenomenon is avoided, and the CAR molecule has important significance in the field of tumor treatment.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and relates to a dual-target chimeric antigen receptor targeting CLL1 and NKG2D ligands and an application thereof. Background technique [0002] In the field of tumor immunotherapy, CAR-T is the most popular tumor immunotherapy method, and it has shown amazing effects in the treatment of leukemia, lymphoma, and multiple myeloma. At present, research on CAR-T products targeting CD19 is relatively in-depth. Kymriah and Yescarta approved in the United States are both CAR-T products targeting CD19 for the treatment of hematological tumors. From a global perspective, the R&D pipeline of CAR-T is rapidly expanding, including the exploration of new targets, such as BCMA, CD123, CD33, etc., and the expansion of new indications, such as the advancement from hematological tumors to solid tumors. The projects of many companies around the world have advanced to the clinical stage, and it is expected th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K19/00C12N15/62C12N15/867C12N5/10A61K39/00A61P35/00
CPCC07K16/2851C07K14/7056C07K14/7051C07K14/70517C07K14/70578C12N15/86C12N5/0636A61K39/001102A61K39/001122A61P35/00C07K2317/56C07K2319/02C07K2319/03C07K2319/33C07K2319/74C12N2740/15043C12N2800/107C12N2510/00A61K2039/5156A61K2039/804
Inventor 李光超罗敏周兆丁雯王学俊
Owner GUANGZHOU BIO GENE TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com